CytomX Therapeutics (NASDAQ:CTMX) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

A number of other research analysts have also commented on the stock. Cantor Fitzgerald initiated coverage on shares of CytomX Therapeutics in a research note on Monday, October 23rd. They issued an “overweight” rating and a $35.00 price target on the stock. Bank of America boosted their price objective on shares of CytomX Therapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, October 4th. Zacks Investment Research downgraded shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Nomura boosted their price objective on shares of CytomX Therapeutics to $44.00 and gave the company a “buy” rating in a report on Wednesday, October 4th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of CytomX Therapeutics in a report on Wednesday, October 4th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $31.88.

CytomX Therapeutics (NASDAQ CTMX) opened at $19.79 on Thursday. CytomX Therapeutics has a 52 week low of $10.40 and a 52 week high of $24.67.

In other CytomX Therapeutics news, Director Frederick W. Gluck sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 26th. The shares were sold at an average price of $17.30, for a total value of $86,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sean A. Mccarthy sold 19,120 shares of the company’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $24.13, for a total transaction of $461,365.60. Following the completion of the transaction, the chief executive officer now owns 23,365 shares of the company’s stock, valued at $563,797.45. The disclosure for this sale can be found here. In the last three months, insiders sold 173,009 shares of company stock valued at $3,835,417. 8.00% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. New York State Common Retirement Fund increased its position in CytomX Therapeutics by 48.8% in the 2nd quarter. New York State Common Retirement Fund now owns 31,100 shares of the biotechnology company’s stock valued at $482,000 after acquiring an additional 10,199 shares during the period. Goldman Sachs Group Inc. acquired a new stake in shares of CytomX Therapeutics during the first quarter worth $190,000. TIAA CREF Investment Management LLC increased its position in shares of CytomX Therapeutics by 183.7% during the second quarter. TIAA CREF Investment Management LLC now owns 169,552 shares of the biotechnology company’s stock worth $2,628,000 after buying an additional 109,791 shares during the period. American Century Companies Inc. acquired a new stake in shares of CytomX Therapeutics during the second quarter worth $922,000. Finally, Sphera Funds Management LTD. increased its position in shares of CytomX Therapeutics by 33.3% during the second quarter. Sphera Funds Management LTD. now owns 200,000 shares of the biotechnology company’s stock worth $3,100,000 after buying an additional 50,000 shares during the period. Hedge funds and other institutional investors own 63.18% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “CytomX Therapeutics (CTMX) Cut to Hold at BidaskClub” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/12/07/cytomx-therapeutics-ctmx-cut-to-hold-at-bidaskclub.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Stock Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related stocks with our FREE daily email newsletter.